Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US8342033094
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG0024L5B86
SLNO
Soleno Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Soleno Therapeutics Inc
ISIN
US8342033094
TICKER
SLNO
MIC
XNAS
REUTERS
SLNO.OQ
BLOOMBERG
SLNO US
Thu, 26.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 26, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the common stock of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inc...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Soleno Therapeutics
US8342033094

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-ma...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Soleno Therapeutics
US8342033094

Key Dates and Disclosure Events Shareholders Need to Know NEW YORK, March 26, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO) to contact the firm. Those who purchased SLNO securities between March 26, 2025 and November 4, 2025 may be entitled to recover damages. Find out if you...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If yo...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, March 25, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO)....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Soleno Therapeutics
US8342033094

Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug SafetyNEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT:...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Soleno Therapeutics
US8342033094

Levi & Korsinsky, LLP alerts investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of a pending securities class action. Class Period: March 26, 2025 through November 4, 2025. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500. A class action has been filed in the U.S....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Soleno Therapeutics
US8342033094

SLNO Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, March 24, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Soleno Therapeutics
US8342033094

NEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encourag...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 24.03.2026       Soleno Therapeutics
US8342033094

SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. Th...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If yo...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Soleno Therapeutics
US8342033094

NEW YORK, March 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both date...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Share...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 22.03.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 22.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT:...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 21.03.2026       Soleno Therapeutics
US8342033094

NEW ORLEANS, March 20, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO), if they purchased or otherwise acquired the Comp...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Soleno Therapeutics
US8342033094

SLNO Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO, March 20, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 20.03.2026       Soleno Therapeutics
US8342033094

BENSALEM, Pa., March 20, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SOLENO THERAPEUTICS, INC. (S...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Soleno Therapeutics
US8342033094

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025?Affected Soleno Therapeutics, Inc. Investor SummaryWho: Soleno Therapeutics, Inc. (NASDAQ: SLNO)What: Securities fraud class action lawsuit filedClass Period: March 26, 2025, through November 4, 2025Deadline to Seek Lead Plaintiff Status: May 5, 2026Key Lawsuit Allegations:...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Share...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Soleno Therapeutics
US8342033094

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 19, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the common stock of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inc...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Soleno Therapeutics
US8342033094

Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug SafetyNEW YORK, March 19, 2026 /PRNewswire/ -- SueWallSt reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased Soleno secur...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT:...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, March 18, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) have opportunity to lead the securities fraud class action lawsuit....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Soleno Therapeutics
US8342033094

SLNO Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, March 18, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Soleno Therapeutics
US8342033094

Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug SafetyNEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT:...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.03.2026       Soleno Therapeutics
US8342033094

Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased Soleno securities between March 26, 2025 and November 4, 2025. YOUR OPTIONS: You may be entitled to compensation without payment...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.03.2026       Soleno Therapeutics
US8342033094

NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encourag...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has al...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Soleno Therapeutics
US8342033094

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2026, inclusive (t...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Soleno Therapeutics
US8342033094

SLNO Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO, March 16, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025....
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Soleno Therapeutics
US8342033094

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jos...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Soleno Therapeutics
US8342033094

SAN DIEGO, March 16, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), have until May 5, 2026 to seek appointment as lead plaintiff of the Soleno class ac...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, March 16, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Soleno Therapeutics
US8342033094

LOS ANGELES, March 16, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Share...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has al...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 15.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has al...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 14.03.2026       Soleno Therapeutics
US8342033094

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025?Affected Soleno Therapeutics, Inc. Investor SummaryWho: Soleno Therapeutics, Inc. (NASDAQ: SLNO)What: Securities fraud class action lawsuit filedClass Period: March 26, 2025, through November 4, 2025Deadline to Seek Lead Plaintiff Status: May 5, 2026Key Lawsuit Allegations:...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 14.03.2026       Soleno Therapeutics
US8342033094

New York, New York--(Newsfile Corp. - March 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"). A class action lawsuit h...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 14.03.2026       Soleno Therapeutics
US8342033094

NEW YORK and NEW ORLEANS, March 13, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO) of a class action securities lawsuit.   CLASS DEFINITION: The...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 14.03.2026       Soleno Therapeutics
US8342033094

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) securities during the period of March 26, 2025 through November 4, 2025, inclusive (“the Class Period”). If you suffered a loss on your Soleno investments...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.03.2026       Soleno Therapeutics
US8342033094

Philadelphia, Pennsylvania--(Newsfile Corp. - March 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). The investigation concerns whether Soleno and certain of its executives violated the federal securities laws by making materially false and misle...
Read more
Soleno Therapeutics
Technical Analysis Termsheets Terminal
Permalink